The company has not filed an annual or quarterly report since its FY2019 10-K, filed Mar 12, 2020. Its latest SEC filing is a EFFECT from Mar 20, 2020.
10-K for FY2019, filed Mar 12, 2020
The sections below describe the company as of the FY2019 annual report.
Develops and commercializes topical medicines for dermatology and licenses foam technology to pharmaceutical companies.
10-K for FY2019, filed Mar 12, 2020
Pharmaceutical companies enter development and license agreements with Foamix, pairing its foam technology with drugs they select; licensees sell the resulting products.
10-K for FY2019, filed Mar 12, 2020
Product launch
Earlier, Foamix described itself as a clinical-stage company developing minocycline foam for acne and rosacea. The latest report describes its acne foam as FDA-approved and available for prescribing, while the rosacea foam remained in development.
20-F for FY2016, filed Feb 21, 2017 10-K for FY2019, filed Mar 12, 2020We are a clinical-stage specialty pharmaceutical company focused on developing and commercializing our proprietary minocycline foam for the…View ↗
Competes with Bausch Health, Mayne Pharmaceuticals, Journey, Almirall, Galderma, LEO, Sol-Gel, Cassiopea, Hovione Farmaciencia, BioPharmX, and Timber Pharmaceuticals
10-K for FY2019, filed Mar 12, 2020Currently marketed products that may compete with AMZEEQ include: (a) oral products such as Solodyn (minocycline, Bausch Health), Doryx…View ↗
Loading...
